AMPH (Amphastar Pharmaceuticals Inc) שיעור רווח גולמי

Amphastar Pharmaceuticals (AMPH) is demonstrating steady commercial growth across its injectable product lines. Analyzing the chart on GURU.Markets, we find that the aggregate gross margin is holding at 44.70. This is based on the company's leadership in the emergency generics sector for the B2B market. High efficiency is achieved through the sale of specialized respiratory therapy drugs and medical consumables.
פילוחי מדדים פיננסיים ומדדי שוק עבור Amphastar Corp (AMPH)

The complexity of producing generic inhalers and stringent FDA oversight provide Amphastar Pharmaceuticals (AMPH) with high market resilience. The company's gross margin reflects the profit share after deducting direct production costs, allowing investors to assess the efficiency of raw material cost management. Monitoring this metric helps detect hidden profitability erosion in advance and prevents overpaying for the asset when analyzing the company's gross margin.